Teal Health, a woman-led company on a mission to get all women and people with a cervix in the US screened for cervical cancer, has been awarded a $1.68 million Small Business Innovation Research (SBIR) Direct to Phase II Grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).
Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New England Journal of Medicine. Drs. Kara Kelly of Roswell Park Comprehensive Cancer Center and Sharon Castellino of Children’s Healthcare of Atlanta and Emory University School of Medicine/Winship Cancer Institute of Emory University served as pediatric leads of this important trial in children and adults with lymphoma.
The findings, published in the Journal of the National Cancer Institute, show that markers of cellular aging—such as DNA damage response, cellular senescence, and inflammatory pathways—significantly increased in all breast cancer survivors, regardless of the type of treatment received.
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.
A novel test developed by Johns Hopkins Kimmel Cancer Center investigators could give gastroenterologists insight into which patients with Barrett’s esophagus — a premalignant condition in which parts of the esophagus become damaged by chronic acid reflux — are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia.
Atrium Health Wake Forest Baptist’s Comprehensive Cancer Center is marking 50 years of National Cancer Institute (NCI) designation.
Researchers aim to transform cancer survivorship care in the U.S. by enhancing the adoption of shared delivery models
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds new light on why tumors that have spread to the brain from other parts of the body respond to immunotherapy while glioblastoma, an aggressive cancer that originates in the brain, does not.
Immunologists have uncovered new approaches to enhance protection from tumors and infections.
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.
The Center for Immunization and Infection Research in Cancer at Moffitt Cancer Center is expanding its viral infection research in Africa. The cancer center has received a $5.5 million, five-year specialized research center grant (U54CA277834) from the National Cancer Institute to investigate virus-associated tumors that disproportionately impact men and women living with HIV in sub-Saharan Africa.
New research shows blood cancers are often misdiagnosed, an NCI grant to develop a urine test for prostate cancer, a surgeon-scientist receives Sylvester’s first DoD grant to study pancreatic cancer, bolstering emergency preparedness for climate-driven disasters, and more are included in this month’s tip sheet .
Long-term exposure to low-dose radiation is linked to an increased risk of cancer, according to a study led by the University of California, Irvine. In the U.S., radiation exposure for the average person doubled between 1985 and 2006, mainly from medical imaging procedures such as CT scans, highlighting the need for its judicious use.
In a new study published and included on the cover of the journal Cancer Research, Moffitt Cancer Center researchers demonstrate how mathematical modeling combined with dynamic biomarkers can be used to characterize metastatic disease and identify appropriate therapeutic approaches to improve patient outcomes.
A study to explore a new way to noninvasively detect prostate cancer is under way at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. The $2.5 million, five-year National Cancer Institute (NCI) grant is led by Sanoj Punnen, M.D.
Led by Washington University School of Medicine in St. Louis and other institutions around the world, the Clinical Proteomic Tumor Analysis Consortium has completed a deep analysis of the proteins driving cancer across multiple tumor types, information that can’t be assessed by genome sequencing alone. Understanding how proteins operate in cancer cells raises the prospect of new therapies.
A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.
Sanford Burnham Prebys’ Cancer Center has received a rare and prestigious Merit Extension Award from the National Cancer Institute (NCI), recognizing and rewarding its earlier accomplishments as well as current research plans. The award extends the center’s current 5-year Cancer Center Support Grant (CCSG) for an additional two years.
20221027104337.jpg&width=400&height=400)
One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.
Sanoj Punnen, M.D., co-chair of the Genitourinary Site Disease Group at Sylvester Comprehensive Cancer Center and associate professor and vice chair of research, Desai Sethi Urology Institute, at the University of Miami Miller School of Medicine, is leading a $2.5 million, five-year National Cancer Institute (NCI) grant to explore a new way to noninvasively detect prostate cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right